To investigate whether LOXL2 contributes to oral fibroblast stimulation by tumor cells via PDGFRs, oral fibroblasts were serum depleted for 24 h and then treated for 24 h with non-CM, CM, CM with PXS-S1C (1 μM) or CM with PDGFR inhibitor AG 1296 (5 μM). This evidence concerns the gene LOXL2 and neoplasm.